Lv1
44 积分 2023-12-13 加入
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
9个月前
已完结
External control arm with real-world Data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes
9个月前
已完结
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
9个月前
已完结
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
9个月前
已完结
IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial
9个月前
已完结
Two-year outcomes post-discharge in Asian patients with acute coronary syndrome: Findings from the EPICOR Asia study
10个月前
已完结
The pharmacokinetics and comparative bioavailabilty of oral and subcutaneous semaglutide in healthy volunteers
10个月前
已完结
The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma
10个月前
已完结
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists
11个月前
已完结
The G Protein-First Mechanism for Activation of the Class B Glucagon-like Peptide 1 Receptor Coupled to N-Terminal Domain-Mediated Conformational Progression
11个月前
已完结
皖公网安备34019202002308
